PDS Biotechnology (NASDAQ:PDSB) Announces Earnings Results, Beats Expectations By $0.08 EPS

PDS Biotechnology (NASDAQ:PDSB) announced its earnings results on Thursday. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.08, Zacks reports.

PDS Biotechnology Stock Performance

Shares of PDSB opened at $1.25 on Friday. The firm’s fifty day simple moving average is $1.41 and its two-hundred day simple moving average is $2.17. PDS Biotechnology has a 12 month low of $1.13 and a 12 month high of $4.56. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $47.74 million, a P/E ratio of -1.08 and a beta of 1.68.

Analysts Set New Price Targets

Separately, HC Wainwright decreased their price target on PDS Biotechnology from $21.00 to $13.00 and set a “buy” rating for the company in a research note on Thursday. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $9.00.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.